Coherus BioSciences, Inc. (CHRS) Financials

CHRS Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 629.6 million 823.0 million
2023-09-30 583.8 million 717.4 million
2023-06-30 469.6 million 644.4 million
2023-03-31 402.4 million 598.9 million

CHRS Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -13.0 million 10.8 million
2023-09-30 -54.3 million 10.0 million
2023-06-30 -39.0 million 10.1 million
2023-03-31 -68.9 million 12.3 million

CHRS Net Income

No data available :(

CHRS Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 117.7 million - 7.5 million
2023-09-30 131.1 million - 5.9 million
2023-06-30 144.7 million 226.2 million 7.1 million
2023-03-31 128.1 million 225.9 million 8.2 million

CHRS Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 111.5 million
2023-09-30 97.7 million
2023-06-30 87.3 million
2023-03-31 79.3 million

CHRS Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 34000 25.3 million 49.5 million -
2023-09-30 - 25.6 million 48.2 million -
2023-06-30 100000 23.3 million 45.1 million -
2023-03-31 152000 34.2 million 49.2 million -

CHRS Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 91.5 million 85.6 million
2023-09-30 74.6 million 32.7 million
2023-06-30 58.7 million 24.8 million
2023-03-31 32.4 million 16.9 million

CHRS

Price: $2.04

52 week price:
1.43
8.65

Earnings Per Share: -2.53 USD

P/E Ratio: -1.03

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Volume: 749400

Ebitda: -55.8 million

Market Capitalization: 251.4 million

Links: